📰 Dose Escalation Study News
Dose Escalation Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Escalation Study. Real-time updates on events, politics, business and more.
May 31, 2024
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
May 23, 2024
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective...
May 22, 2024
22.05.2024 - Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted ...
May 2, 2024
Results of a Phase 1, Open-label,Dose-escalation Study of Gene Therapy with AAV2-hAQP1 as Treatment for Grade 2 and 3 Radiation-induced Late Xerostomia and Parotid Gland Hypofunction -...
April 24, 2024
REDWOOD CITY, Calif., April 24, 2024 -- Coherus BioSciences, Inc. today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the...
April 24, 2024
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of...
April 24, 2024
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data
January 8, 2024
KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical ne...
January 8, 2024
, 01/08/2024 / 07:01, EST/EDT - EQS Newswire - Tryp Therapeutics Inc. (Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Canadian Stock Exchange, Nasdaq OTC)KELOWNA BC / ACCESSWIRE / January 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a...
November 11, 2023
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]